DR. TOMMY EUGENE HOWARD, M.D.
Medical Practice in Los Angeles, CA
License number
California 039131
Category
Medical Practice
Type
Medical Genetics, Ph.D. Medical Genetics
Address
Address
2
11301 Dept. Of Pathology & Laboratory Medicine BLDG 500, Los Angeles, CA 90073
1500 Voorhees Ave, Manhattan Beach, CA 90266
1500 Voorhees Ave, Manhattan Beach, CA 90266
Phone
(310) 478-3711
(310) 268-4983 (Fax)
(404) 597-8014
(310) 268-4381 (Fax)
(310) 268-4983 (Fax)
(404) 597-8014
(310) 268-4381 (Fax)
Personal information
See more information about TOMMY EUGENE HOWARD at radaris.comName
Address
Phone
401 W La Veta Ave APT 31, Orange, CA 92866
43020 Alexo Dr, Lancaster, CA 93536
2823 San Leandro Blvd APT 203, San Leandro, CA 94578
3900 Saffron Ct, Bakersfield, CA 93309
337 Delaware Rd, Burbank, CA 91504
Professional information
Tommy Eugene Howard, Los Angeles CA
Specialties:
Pathology, Anatomic Pathology & Clinical Pathology, Clinical Pathology
Work:
Va Greater Los Angeles Healthcare System
11301 Wilshire Blvd, Los Angeles, CA 90073
11301 Wilshire Blvd, Los Angeles, CA 90073
Education:
Emory University(1993)
Dr. Tommy E Howard, Los Angeles CA - MD (Doctor of Medicine)
Specialties:
Internal Medicine, Pediatrics
Address:
11301 Wilshire Blvd SUITE 500, Los Angeles 90073
(310) 478-3711 (Phone), (310) 268-4983 (Fax)
(310) 478-3711 (Phone), (310) 268-4983 (Fax)
Certifications:
Internal Medicine, 2005, Pediatrics, 2013
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Emory University
Graduated: 1993
Emory University
Graduated: 1993
Compositions And Methods Of Treatment Of Black Hemophiliac Patients
US Patent:
2012029, Nov 22, 2012
Filed:
Oct 16, 2009
Appl. No.:
13/502292
Inventors:
Tommy Eugene Howard - Manhattan Beach CA, US
International Classification:
A61K 38/37, A61P 7/04, A01K 67/00, C07K 14/755, C12Q 1/68
US Classification:
800 13, 514 141, 530383, 435 611
Abstract:
It has been determined that most mutations in factor VIII occur in multiple haplotypes, not primarily in one haplo-type. The frequencies of mild, moderate, and severe hemophilia did not differ significantly according to the background haplo-type. The odds of having inhibitor were significantly higher among patients in the H3+H4 haplotype groups as compared to H1+H2 haplotype groups. This association appears to be independent of the mutation. The results indicate that white hemophiliacs should be treated with Kogenate®. However, it would clearly be of benefit to assess the haplotype of black hemophiliacs prior to prescribing the recombinant FVIII to be used for treatment. It is not essential to determine the actual mutations responsible for the hemophilia prior to prescribing the recombinant FVIII. Also described are transgenic human FVIII animal models.
Predicting And Reducing Alloimmunogenicity Of Protein Therapeutics
US Patent:
2011017, Jul 21, 2011
Filed:
Jan 14, 2011
Appl. No.:
13/007403
Inventors:
Tommy Eugene Howard - Manhattan Beach CA, US
International Classification:
A61K 39/00, C07H 21/04, C12Q 1/68, A61K 31/7088, A61K 35/16, G01N 33/567, A61P 37/04, A61P 37/06, A61P 7/04
US Classification:
4241841, 536 232, 435 611, 514 44 R, 424530, 435 724
Abstract:
Methods of predicting the immunogenicity of a therapeutic protein in a subject are provided and the use of this method in selecting a protein for replacement therapy having the fewest immunogenic epitopes. The method is demonstrated by reference to ADAMTS13. Isolated allelic variants of ADAMTS13 that contribute to the variability in risk for both arterial and venous thrombotic disease development are provided. The allelic variants are identified as single nucleotide polymorphisms (ns-SNPs) in the ADAMTS13 gene, which result in haplotypes identified as H1 to H14. A method for improving outcomes of transfusions/transplant products is also provided by selection of haplotype matched therapeutics.